Baird Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $16

Benzinga Newsdesk www.benzinga.com Negative 92.8%

Neg 92.8% Neu 0% Pos 0%

Baird analyst Joel Beatty downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Outperform to Neutral and lowers the price target from $40 to $16.